. 2022 May 18;19:7. doi: 10.1186/s12977-022-00592-6

Table 2.

Summary of anti-BLV antibody detection in human serum by ELISA

2nd Antibody	Human sera specimens		Control experiment
	Human sera specimens		Bovine sera				Human sera
	BLV gp51^a ELISA (N = 97)	BLV p24^a ELISA (N = 97)	BLV gp51 ELISA^b		BLV p24 ELISA^b		HTLV-I/II ELISA^c
	BLV gp51^a ELISA (N = 97)	BLV p24^a ELISA (N = 97)	BLV (+) (N = 2)	BLV (−) (N = 1)	BLV (+) (N = 2)	BLV (−) (N = 1)	HTLV (+)	HTLV (−)
Goat anti-human IgG (HRP)	0/97	0/97	0/2	0/1	0/2	0/1	2/2	0/2
Goat anti-human IgM (HRP)	0/97	0/97	0/2	0/1	0/2	0/1	2/2	0/2
Rabbit anti-bovine IgG (HRP)	NT	NT	2/2	0/1	2/2	0/1	0/2	0/2

^aBLV gp51 and p24 ELISAs in BLV gp51 and p24 antigens coated plates was performed using 50-fold-diluted human serum specimens as primary antibody following either HRP-conjugated goat anti-human IgG or HRP-conjugated goat anti-human IgM as secondary antibody. NT indicates not tested

^bBLV gp51 and p24 ELISAs was performed using two BLV-infected cattle and one cattle with no BLV infection, as positive and negative controls, respectively, followed by HRP-conjugated anti-bovine IgG, as second antibody to check the validity of the experiment procedure

^cHTLV I/II antibody ELISA was performed using human HTLV I/II positive antibody and negative antibody, followed by HRP-conjugated goat anti-human IgG and IgM in replacement with the second antibody in the kit to validate whether anti-human second antibodies HRP-conjugated goat anti-human IgG and IgM used in our study are actively working or not